Dear Editor: Dr Abidi and Dr Bhaskara have accurately described new concerns arising from the use of atypical antipsychotics (1) . The pharmacotherapy of schizophrenia remains an ongoing challenge for researchers and clinicians. The atypicals cause fewer extrapyramidal side effects (EPSEs) and tardive dyskinesia (TD), but there is growing concern regarding their significant long-term adverse metabolic and cardiac effects. These risks may be comparable to the EPSEs and TD associated with typical antypsychotics. Since atypical antipsychotics are all equally effective, the choice of drug for any given patient is still determined by their relative adverse-effect profile. Thus early identification of patients at high risk for obesity, diabetes, and cardiac disease is essential and requires increased monitoring and management (1).
Freedman (2) has recently described the current knowledge about the psy chopharmacologic treatment of schizophrenia, a chronic and debilitating psychotic mental disorder wherein the similar therapeutic response among the new drugs emphasizes that choice be determined by the side effects profile.
The suffering of schizophrenia patients, as well as the disorder's economic and social costs, is always underestimated. Schizophrenia has a considerable impact on patients, their families, and the health care system (3). Most patients experience repeated episodes with worsening outcomes: 9% suffer lasting impairment, and 43% endure increasingly severe symptoms with no periods of complete remission (4). Schizophrenia patients face impoverished lifestyles, finding it difficult to secure paid employment and to hold on to their jobs when they get them. The development and more widespread use of atypical antipsychotics may lead to a short-term increase in the the proportion of the total cost of schizophrenia attributable to medications. Conversely, their use may lead to reduced hospitalization and allow patients to work and lead a normal social life, apart from the still-unknown cost of dealing with metabolic and cardiac side effects. Early diagnosis and precise treatment with the safest possible antipsychotics are key elements for lowering the social and economic burden of schizophrenia, but clinicians should be aware of the new side effects associated with long-term use of atypical antypsychotics.
Reply: From Chlorpromazine to Clozapine-Antipsychotic Adverse Effects and the Clinician's Dilemma
Dear Editor: We thank Dr Nardi for his comments, which underscore the points we made and the challenges we face in treating schizophrenia.
In evaluating the personal, social, and economic burden of schizophrenia, we need to consider not only the immediate gains but also the long-term sequelae of pharmacotherapy.
Regulatory bodies such as Canada's Therapeutic Products Directorate, the US Food and Drug Administration, and other similar agencies usually base their approval for antipsychotic drugs on a few Phase III clinical trials, where the study drug or treatment is given to large groups of people (approximately 1000 to 3000) to confirm its effectiveness, monitor its side effects, compare it with commonly used treatments, and collect information that will allow it to be used safely. In most cases, these are short-term, double-blind, placebo-controlled trials. Further, in seeking approval, pharmaceutical firms are not obligated to submit all data (both positive and negative) from Phase III clinical trials. Therefore, continued postmarketing vigilance and surveillance play a crucial role in evaluating long-term risks and benefits.
Srinivasa M Bhaskara, MB, FRCPC, MRCPsych S Abidi, MD Lower Sackville, Nova Scotia
Autism: Multiple Genes Acting on a Distributed Neural Target?
Dear Editor: Genetic research on the autistic spectrum disorders (ASDs) needs an informative endophenotype (1) , that is, a common denominator that would distinguish brain functioning in the ASDs from normal functioning. In physiological functioning, simple reproduction of inputs takes place in primary sensorial areas, and integration of congruent unimodal data into more significative multimodal ones is enacted in associative areas (2) . Higher levels of categorization and understanding are progressively reached, and a final choice among many (often emotionally charged) options guides voluntary and adaptive actions. The amount of data to be computed increases exponentially through all those stages. Enlarging webs of neural organizations cooperate for the purpose, continuously and smoothly changing their configuration and distribution of activation. It is difficult to conceive this kind of functioning without the intervention of a modulatory system (3) to integrate and set priorities among incoming and outgoing data. In a recent Positron Emission Tomography study, Hall and others found that individuals with autism are less prone to associate inputs from different sensorial modalities and that they preferentially allocate attentional resources to partial features of stimuli (4) . In autism, we clinically detect fragmented mental performances, which tend to be run as isolated processes instead of multiple parallel and interlinked ones. Thus children aged 2 years who have autism and good single-word 784 W Can J Psychiatry, Vol 49, No 11, November 2004
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